Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets (12.5mg Empagliflozin / 1000mg Metformin HCl) Versus Synjardy® 12.5mg/1000mg Film-coated Tablets (12.5mg Empagliflozin/ 1000mg Metformin HCl) in Healthy Subjects Under Fed Conditions

NCT06450262 is registered in ClinicalTrials.gov with Humanis Saglık Anonim Sirketi as lead sponsor.

NCT NCT06450262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06450262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Two-way, Two-period, Single Oral Dose, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin/ Metformin HCl 12.5mg/1000mg Film-coated Tablets (12.5mg Empagliflozin / 1000mg Metformin HCl) Versus Synjardy® 12.5mg/1000mg Film-coated Tablets (12.5mg Empagliflozin/ 1000mg Metformin HCl) in Healthy Subjects Under Fed Conditions
Lead sponsor
Humanis Saglık Anonim Sirketi
Phase
Phase 1
Overall status
Completed
Start date
January 4, 2024
Completion date
March 5, 2024
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type2diabetes